Inclusion-Body Myositis Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Phenotypic spectrum of inclusion body myositis
Clin Exp Rheumatol. 2024 Feb 28. doi: 10.55563/clinexprheumatol/fhrx3q. Online ahead of print.ABSTRACTInclusion body myositis (IBM) is a progressive, debilitating muscle disease commonly encountered in patients over the age of 50. IBM typically presents with asymmetric, painless, progressive weakness and atrophy of deep finger flexors and/or quadriceps muscle. Many patients with IBM develop dysphagia. However, atypical presentations of IBM with isolated dysphagia, asymptomatic hyper-CKemia, foot drop, proximal weakness, axial weakness, and facial diplegia have been reported. Other acquired and some inherited disorders may ...
Source: Clinical and Experimental Rheumatology - March 4, 2024 Category: Rheumatology Authors: Bhaskar Roy Mazen M Dimachkie Elie Naddaf Source Type: research

Does inspiratory muscle training improve lung function and quality of life in people with inclusion body myositis? A pilot study
Inclusion body myositis (IBM) is an insidious, inflammatory neuromuscular disease, and the most common acquired muscle disease in middle to older-aged adults [1]. IBM is characterised clinically by muscle weakness in the knee extensors and forearm flexors and pathologically on muscle biopsy revealing inflammation, rimmed vacuoles and protein deposits, known as inclusions [1,2]. Furthermore, the prevalence of dysphagia and subsequent aspiration pneumonia is also high, being the largest cause mortality for patients with IBM [3]. (Source: Neuromuscular Disorders)
Source: Neuromuscular Disorders - February 21, 2024 Category: Neurology Authors: Ethan Williams, Ian Cooper, Kelly Beer, Kathryn Hird, Vinicius Cavalheri, Kathryn Watson, Merrilee Needham Source Type: research

Imaging swallowing function and the mechanisms driving dysphagia in inclusion body myositis
Clin Exp Rheumatol. 2024 Feb 16. doi: 10.55563/clinexprheumatol/t1x3qa. Online ahead of print.ABSTRACTSporadic inclusion body myositis (IBM) is a progressive condition which commonly affects patients aged above 40. IBM does not respond to immunosuppression and no proven treatments are available. Up to 80% of patients develop some degree of swallowing impairment during the disease course. Dysphagia is a source of marked morbidity in IBM and predisposes patients to life-threatening complications such as aspiration pneumonia. The pathophysiology behind dysphagia in IBM is not fully understood. Evidence from imaging demonstrat...
Source: Clinical and Experimental Rheumatology - February 19, 2024 Category: Rheumatology Authors: Sharfaraz Salam Jodi Allen Mazen M Dimachkie Michael G Hanna Pedro M Machado Source Type: research

Intravenous immunoglobulin in the treatment of sporadic inclusion body myositis: time for new evidence?
Clin Exp Rheumatol. 2024 Feb 19. doi: 10.55563/clinexprheumatol/7x5o3q. Online ahead of print.NO ABSTRACTPMID:38372729 | DOI:10.55563/clinexprheumatol/7x5o3q (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - February 19, 2024 Category: Rheumatology Authors: Lorenzo Fontanelli Gabriele Vadi Erika Schirinzi Giulia Di Rauso Gabriele Bellini Giulia Ricci Gabriele Siciliano Source Type: research